Importance Exercise limitation is a cardinal manifestation of heart failure with reduced
ejection fraction (HFrEF) but is not consistently improved by any of the current guideline …

Abstract Background In GALACTIC-HF (Global Approach to Lowering Adverse Cardiac
outcomes Through Improving Contractility in Heart Failure)(n= 8,256), the cardiac myosin …

Omecamtiv mecarbil is a selective, small-molecule activator of cardiac myosin that is being
developed as a potential treatment for heart failure with reduced ejection fraction. Here we …

Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) are common heart
muscle disorders that are caused by pathogenic variants in sarcomere protein genes. HCM …

Several lines of evidence suggest that the primary effect of hypertrophic cardiomyopathy
mutations in human β-cardiac myosin is hypercontractility of the heart, which leads to …

Heart failure (HF) is an important cardiovascular disease because of its increasing
prevalence, significant morbidity, high mortality, and rapidly expanding health care cost. The …

Mitochondria ensure the supply of cellular energy through the production of ATP via
oxidative phosphorylation. The alteration of this process, called mitochondrial dysfunction …

The term “inotrope” is familiar and intimately connected with pharmaceuticals clinically used
for treatment of low cardiac output with cardiogenic shock. Traditional inotropic agents exert …

Worsening heart failure (WHF) is a severe and dynamic condition characterized by
significant clinical and hemodynamic deterioration. It is characterized by worsening HF …

The fundamental basis of muscle contraction 'the sliding filament model'(;) and the 'swinging,
tilting crossbridge-sliding filament mechanism'(;) nucleated a field of research that has …